Cargando…
Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?
Autores principales: | Roh, Ji Woong, Kim, Yongcheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257154/ https://www.ncbi.nlm.nih.gov/pubmed/35656934 http://dx.doi.org/10.4070/kcj.2022.0105 |
Ejemplares similares
-
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention
por: Park, Jiesuck, et al.
Publicado: (2022) -
Successful Primary Percutaneous Coronary Intervention without Stenting: Insight from Optimal Coherence Tomography
por: Roh, Ji Woong, et al.
Publicado: (2022) -
Feasibility and Safety of the Left Distal Radial Approach in Percutaneous Coronary Intervention for Bifurcation Lesions
por: Lee, Oh-Hyun, et al.
Publicado: (2021) -
Long-Term Beta-Blocker Therapy in Patients With Stable Coronary Artery Disease After Percutaneous Coronary Intervention
por: Lee, Seung-Jun, et al.
Publicado: (2022) -
Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
por: Lee, Pil Hyung, et al.
Publicado: (2020)